This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Includes the Inaugural North American Viral Hepatitis Elimination Summit

Program

VIRTUAL PLATFORM ACCESS

Click Here to access the CLM Virtual Platform.

Reach out to clm_reg@mci-group.com for any assistance with logging in.

*Subject to Change

Times are in Eastern Daylight Time (EDT)

Wednesday, May 5, 2021

  • 09:30 10:00

    BREAK | VISIT THE VIRTUAL EXHIBITION

  • 09:30 10:00

    BREAK | SYMPOSIUM

    Moderator: Marco Puglia

    Shifting Goalposts: Risk-Based Treatment of PBC
    | Mark Swain
    Evaluating risk in PBC: Practical Application of Scoring Systems

    This education session is an unaccredited learning activity, with content developed by the speaker, and was made possible with the support of Intercept Pharma

  • 10:00 11:00

    Concurrent Sessions

    CLM Symposium 3 – Addressing Disparities and Controversies in End-Stage Liver Diseases
    Moderator: Mayur Brahmania

    10:00 - 10:15 | Liver Disease in 2021: Addressing Disparities, Challenges from COVID-19 | Carla Brady, Medical Expert, Health Advocate, Leader

    10:15 - 10:30 | HCC in 2021 | Nicole Rich, Medical Expert, Leader

    10:30 - 10:45 | Transplant (to Include Organs from MAID, Inter-Provincial Travel, Access Issues with Distance and Treatment) | David Goldberg, Medical Expert, Leader

    10:45 - 11:00 | Discussion

    CLM Symposium 4 – Translational Research in HCC and Liver Disease
    Moderator: Sonya MacParland

    10:00 - 10:15 | Immune Based Approaches to Treating HCC | Tim Greten, Medical Expert, Scholar

    10:15 - 10:30 | Risk Algorithms for Predicting HCC (to Include Novel Molecular Algorithms) | Hashem El-Serag, Medical Expert, Scholar

    10:30 - 10:45 | Formation of Giant Kupffer Cells: A Potentially Life-Saving Adaptation by Monocytes in Chronic Liver Disease | Paul Kubes, Medical Expert, Scholar

    10:45 - 11:00 | Discussion

  • 10:30 11:55

    CAHN Session & Closing Remarks

    End Stage Liver Disease Management
    Moderator: Elizabeth Lee


    10:30 - 10:50 | Diagnosis of Cirrhosis | Lesa Chisholm

    10:50 - 11:10 | Nutrition and ESLD | Vanessa Den-Heyer

    11:10 - 11:30 | Diagnosis and Management of Ascites | Lisa Douglas

    11:30 - 11:50 | Palliative care: when, what and how? | Colina Yim & Elizabeth Lee

    11:50 - 11:55 | Closing Remarks | Donna Zukowski

  • 11:00 12:00

    CASL‑CLF Sass‑Kortsak Award Presentation & Lecture

    11:00 - 11:15 | Award Presentation & Introductions | Jennifer Nebesky & Vicky Ng

    11:15 - 12:00 | Intestinal Failure Associated Liver Disease: the Gut – Lipid – Liver Axis | Ronald Sokol, Medical Expert, introduced by Vicky Ng

  • 12:00 13:00

    Concurrent Sessions

    NAFLD – New Developments
    Moderator: Saumya Jayakumar

    12:00 - 12:15 | Adult: Addressing Disparities in Patients with NAFLD from Diagnosis to Transplant | Zobair Younossi, Medical Expert

    12:15 - 12:30 | Pediatric NAFLD - Progress and Ongoing Challenges | Miriam Vos,Medical Expert, Leader

    12:30 - 12:45 | Overview of new NAFLD Therapies | Keyur Patel

    12:45 - 13:00 | Discussion

    Quality Metrics for Cirrhosis Care
    This session was co-developed with Lupin and was planned to achieve scientific integrity, objectivity and balance.
    Moderator: Erin Kelly

    12:00 - 12:15 | How Does Canada Develop Metrics Relating to Cirrhosis Care? Lessons from the Cirrhosis Collaborative Care Network | Elliot Tapper, Medical Expert, Leader, Collaborator

    12:15 - 12:30 | Coordinated Cirrhosis Care: The Alberta Model | Puneeta Tandon, Medical Expert, Leader

    12:30 - 12:45 | Defining Outcomes in Pediatric Liver Disease and Cirrhosis | Simon Lam

    12:45 - 13:00 | Discussion

  • 13:00 13:30

    BREAK | VISIT THE VIRTUAL EXHIBITION

  • 13:00 13:30

    Break | Meet the Expert session

    The Science of Obesity, Current Treatments and New Targets | Sean Wharton

    This education session is an unaccredited learning activity, with content developed by the speaker, and was made possible with the support of Novo Nordisk.

  • 13:30 14:30

    Concurrent Sessions

    Transplant Controversies and New Developments
    Moderator: Anouar Teriaky

    13:30 - 13:45 | Cardiac Risk Assessment Pre-Transplant, Post-Transplant | Lisa VanWagner

    13:45 - 14:00 | HCC: Pushing the Size Limits Yes vs. No Debate | James Shapiro

    14:00 - 14:15 | HCC: Pushing the Size Limits Yes vs. No Debate |  Neil Mehta, Medical Expert, Leader

    14:15 - 14:30 | Debate Rebuttal & Discussion

    Approach to Special Populations and Liver Disease
    Moderator: Orlee Guttman

    13:30 - 13:45 | Cirrhosis and Pregnancy: Outcomes in Mothers and Infants | Jennifer A. Flemming, Medical Expert

    13:45 - 14:00 | Autoimmune Hepatitis and PSC in Children and Adolescents | Nitika Gupta, Medical Expert

    14:00 - 14:15 | The Role of Telemedicine to Optimize Patient Care | Hemant Shah, Leader, Communicator, Professional

    14:15 - 14:30 | Discussion

  • 14:30 15:30

    Oral Presentations

    PANEL 3
    Moderator: Juan Gonzales Abraldes


    14:30 - 14:40 | Younger Age Is Associated With Lower Self-Reported Quality Of Life Among Patients With Autoimmune Liver Disease During Canada's Response To The Covid-19 Pandemic | Christina G. Plagiannakos

    14:40 - 14:50 | Hepatolithiasis Is A Frequent And Prognostic Finding In Patients With Primary Sclerosing Cholangitiss | Bellal Jubran

    14:50 - 15:00 | Machine Learning Approach To Predict Cardiovascular Diseases In Patients With Nafld In The Uk Biobank Cohorts | Neta Brender Gotlieb

    15:00 - 15:10 | The Ontario Alcohol-Related Liver Disease Pilot Project: Liver Transplant For Patients With Less Than Six Months Of Abstinence | Jill Quance

    15:10 - 15:30 | Q&A

    PANEL 4
    Moderator: Carla Coffin
    , Health Advocate, Medical Expert

    14:30 - 14:40 | The Alarming Impact Of Covid-19 Pandemic On Alcohol-Related Liver Disease: A Population-Based Canadian Study | Abdel Aziz Shaheen

    14:40 - 14:50 | Comparative Analysis Of The Expression And Significance Of Glutamine Transporters In Hepatocellular Carcinoma And Normal Liver. | Vincent Tambay

    14:50 - 15:00 | Obeticholic Acid Improves Transaminases In Patients With Non-Alcoholic Steatohepatitis: Results From The 18-Month Interim Analysis Of The Regenerate Study | Keyur Patel

    15:00 - 15:10 | Omics Approach Towards Understanding The Etiology Of Primary Sclerosing Cholangitiss | Kiandokht Bashiri

    15:10 - 15:30 | Q&A

  • 15:30 16:30

    CLF‑CASL Gold Medal Award Presentation and Lecture

    15:30 - 15:45 | Award Presentation & Introductions | Jennifer Nebesky & Carla Coffin, Health Advocate, Medical Expert

    15:45 - 16:30 | Ars longa, vita brevis: lessons learned from a life in Hepatology | Samuel Lee, Professional, introduced by Paul Adams

  • 16:30 17:00

    CASL Awards Ceremony and Closing Remarks

    Jordan Feld, Health Advocate, Medical Expert
    John Ward